MUHIBA BEGUM: Open Payments
NPI 1821716994 · EMERSON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,821 in 59 payments from 11 companies in 2025. Trend: 2023 $64 · 2024 $503 · 2025 $1,821
Food & beverage: $1,821
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $350 |
| Vanda Pharmaceuticals Inc. | 6 | $272 |
| Neurocrine BioSciences, Inc. | 9 | $236 |
| Otsuka America Pharmaceutical, Inc. | 6 | $204 |
| Alkermes, Inc. | 6 | $193 |
| Almatica Pharma LLC | 11 | $153 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $120 |
| Axsome Therapeutics, Inc. | 1 | $117 |
| Teva Pharmaceuticals USA, Inc. | 1 | $109 |
| E.R. Squibb & Sons, L.L.C. | 3 | $50 |
Products named: VRAYLAR, FANAPT, INGREZZA, REXULTI, LOREEV XR, LYBALVI, CAPLYTA, Auvelity.
Industry payments across NJ — which companies pay providers there.
